Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health disorders, has announced the appointments of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board. The additions are expected to significantly enhance the company's expertise in biotechnology, drug delivery, and central nervous system clinical development as it advances its pipeline of therapeutic candidates.
Dr. Robert Langer is a renowned figure in biotechnology, known for his pioneering work in drug delivery systems. His contributions to the field have led to numerous innovations that have transformed medical treatments. Dr. Stephen Brannan brings extensive experience in central nervous system clinical development, having led multiple programs in psychiatry and neurology. Their insights are expected to support Helus Pharma's disciplined, evidence-based approach to developing treatments for major depressive disorder (MDD) and generalized anxiety disorder (GAD).
Helus Pharma is currently advancing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of MDD. This program has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, underscoring its potential to address a significant unmet need. Additionally, the company is developing HLP004, another proprietary NSA in Phase 2 trials for GAD. These programs aim to provide durable improvements in mental health by activating serotonin pathways believed to promote neuroplasticity.
The appointments come at a critical time when mental health conditions are increasingly recognized as a global health priority. With millions of people suffering from depression and anxiety, the need for effective treatments is more urgent than ever. Helus Pharma's NSAs are designed to offer new options for patients who do not respond adequately to existing therapies. The company's focus on synthetic molecules that target serotonin pathways represents a novel approach that could potentially reshape the treatment landscape.
For more details on the announcement, the full press release is available at https://ibn.fm/CyjTq. Helus Pharma, operating under the commercial name Cybin Inc., was founded in 2019 and operates in Canada, the United States, the United Kingdom, and Ireland. The company continues to expand its research portfolio of investigational NSAs, aiming to address the large unmet need for people suffering from mental health conditions.
The addition of Dr. Langer and Dr. Brannan to the Scientific Advisory Board is a strategic move that reinforces Helus Pharma's commitment to rigorous science and innovation. Their guidance is expected to accelerate the development of the company's pipeline and enhance its ability to bring transformative treatments to patients. As Helus Pharma progresses its clinical programs, the industry will be watching closely to see how these developments impact the mental health treatment paradigm.
